Similar articles

• An inactivated subvirion influenza A (H5N1) vaccine.

  Focosi D. Focosi D. N Engl J Med. 2006 Jun 22;354(25):2724-5; author reply 2724-5. N Engl J Med. 2006. PMID: 16795150 No abstract available.
• Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

  Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Treanor JJ, et al. N Engl J Med. 2006 Mar 30;354(13):1343-51. doi: 10.1056/NEJMoa055778. N Engl J Med. 2006. PMID: 16571878 Clinical Trial.
• Vaccines against avian influenza--a race against time.

  Poland GA. Poland GA. N Engl J Med. 2006 Mar 30;354(13):1411-3. doi: 10.1056/NEJMe068047. N Engl J Med. 2006. PMID: 16571885 No abstract available.
• Pandemic H5N1 influenza vaccine development: an update.

  El Sahly HM, Keitel WA. El Sahly HM, et al. Expert Rev Vaccines. 2008 Mar;7(2):241-7. doi: 10.1586/14760584.7.2.241. Expert Rev Vaccines. 2008. PMID: 18324892 Review.
• Influenza A (H5N1) pandemic prototype vaccine Fluval.

  Vajo Z. Vajo Z. Expert Rev Vaccines. 2009 May;8(5):619-24. doi: 10.1586/erv.09.25. Expert Rev Vaccines. 2009. PMID: 19397418 Review.